Cargando…

Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a novel class of hypoglycemic drugs, show excellent cardiovascular benefits, and have further improved heart failure outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status. However, the efficacy of SG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Huayang, Zhang, Yitao, Wang, Shunjun, Yue, Yuan, Liu, Quan, Huang, Suiqing, Peng, Huajing, Zhang, Yi, Zeng, Weijie, Wu, Zhongkai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591217/ https://www.ncbi.nlm.nih.gov/pubmed/34790128 http://dx.doi.org/10.3389/fphar.2021.756226

Ejemplares similares

Notopterol Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat
por: Huang, Lin, et al.
Publicado: (2022)

Alternatively Expressed Transcripts Analysis of Non-Small Cell Lung Cancer Cells under Different Hypoxic Microenvironment
por: Wang, Shunjun, et al.
Publicado: (2021)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
por: Tang, Yi, et al.
Publicado: (2022)

Hypoxia inducible factor signaling and experimental persistent pulmonary hypertension of the newborn
por: Wedgwood, Stephen, et al.
Publicado: (2015)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
por: Zhang, Ruihua, et al.
Publicado: (2022)

Therapeutic Strategies in Pulmonary Hypertension
por: Fuso, Leonello, et al.
Publicado: (2011)

Role of heparanase in pulmonary hypertension
por: Wang, Lin-Jun, et al.
Publicado: (2023)

Advances in the research of sulfur dioxide and pulmonary hypertension
por: Liu, Xin, et al.
Publicado: (2023)

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease
por: Chen, Chung-Yu, et al.
Publicado: (2021)

Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension
por: Wang, Yu, et al.
Publicado: (2018)

Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
por: Zhang, Xue, et al.
Publicado: (2019)

Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway
por: Zuo, Wanyun, et al.
Publicado: (2021)

Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension
por: Jasemi, Seyed Vahid, et al.
Publicado: (2020)

Circulating Plasma miRNA and Clinical/Hemodynamic Characteristics Provide Additional Predictive Information About Acute Pulmonary Thromboembolism, Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Hypertension
por: Fabro, Alexandre Todorovic, et al.
Publicado: (2021)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension
por: He, Yang-Yang, et al.
Publicado: (2021)

Regulatory T Cell-Related Gene Indicators in Pulmonary Hypertension
por: Liu, Yan, et al.
Publicado: (2022)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Evaluating the therapeutic role of selected active compounds in Plumula Nelumbinis on pulmonary hypertension via network pharmacology and experimental analysis
por: Xiao, Xinghua, et al.
Publicado: (2022)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension
por: Zhu, Zhongkai, et al.
Publicado: (2019)

Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats
por: Xia, Jingwen, et al.
Publicado: (2018)

Corrigendum: Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension
por: He, Yang-Yang, et al.
Publicado: (2021)

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension
por: Chen, Yong-Jie, et al.
Publicado: (2021)

Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
por: Bao, Ya-Ru, et al.
Publicado: (2020)

Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition
por: Wu, Yonghui, et al.
Publicado: (2021)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
por: Alencar, Allan K. N., et al.
Publicado: (2017)

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
por: Tong, Yi, et al.
Publicado: (2018)

Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension
por: Shi, Yinan, et al.
Publicado: (2021)

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
por: Tettey, Abraham, et al.
Publicado: (2021)

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
por: Qiao, Panshuang, et al.
Publicado: (2022)

Conditioned medium from M2b macrophages modulates the proliferation, migration, and apoptosis of pulmonary artery smooth muscle cells by deregulating the PI3K/Akt/FoxO3a pathway
por: Huang, Suiqing, et al.
Publicado: (2020)

Supplementation with Tex261 provides a possible preventive treatment for hypoxic pulmonary artery hypertension
por: Chen, Shaokun, et al.
Publicado: (2022)

Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline
por: Qin, Tianyou, et al.
Publicado: (2022)

Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
por: Yu, Jing, et al.
Publicado: (2021)

New hope for Nutlin-3a therapy for pulmonary arterial hypertension
por: Fukumoto, Jutaro, et al.
Publicado: (2013)

Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension
por: Xue, Zhifeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v33rgpbts0mohmea4u7o0ladf1